June 2025 marked a month of significant progress in cancer care, as the FDA approved several new therapies and treatment combinations across a range of cancer types. As reported by…
A significant milestone has been achieved in the fight against blood cancers, as the first patient has been dosed in a pivotal Phase 3 clinical trial evaluating a promising new…
Anixa Biosciences has reached a new milestone in the development of its innovative CAR-T cell therapy, announcing the dosing of the first patient in the fourth cohort of its ongoing…
Treating cancer can be challenging. While there are many different potential therapeutic options designed for people with cancer, these treatments are not always effective. Chimeric antigen receptor (CAR) T cell…
September is recognized as Blood Cancer Awareness Month, a time of year to help spread awareness about blood malignancies among the general public and the medical community. In order to…
Marco and India Biviano felt like something bad was happening to their young son Luca. His stomach was distended and painful. Luca frequently developed chest infections that required round after…
According to a press release from the US Food and Drug Administration (FDA), the agency recently approved a new treatment for multiple myeloma, a type of rare blood cancer. The…
An unsettling fact: every three minutes, someone in the United States is diagnosed with some form of blood cancer. September is Blood Cancer Awareness Month to help raise awareness…
In 1873, a Russian physician coined the term “multiple myeloma” after discovering a patient with eight different forms of bone marrow tumors. In the early years, patients were treated with…
The drug development process is not always easy or quick. It consists of drug discovery, preclinical and clinical research, and FDA approval. However, sometimes developers are sent back to the…
Ionis and the University of California, San Diego (UCSD) have formed a team to investigate antisense oligonucleotide technology as a treatment for multiple myeloma. Their drug, ION251, has shown positive…
According to a story from newswise.com, a team of researchers from the University of New Hampshire may have discovered the next new treatment for a rare form of blood cancer…
In a recent press release, Swedish biotechnology company Active Biotech announced that the first patient in their Phase 1b/2a clinical trial received a dose of tasquinimod. The trial will…
According to CLL Pharmacist, results from the Phase 3 GENUINE trial show that, when taken in conjunction, ibrutinib and ublituximab lead to better patient outcomes than either drug alone.…
PharmaEssentia Corporation, a biopharmaceutical company located in Burlington, Massachusetts, has recently seen their Biologics License Application (BLA) approved by the FDA. This application was submitted for ropeginterferon alfa-2b, a treatment…
Orlando-based healthcare company AdventHealth developed a novel immunotherapy treatment designed to treat patients with AML and MDS whose conditions failed to respond to other treatments. In addition, the organization is…
As reported in Guru Focus, biotech company Protagonist Therapeutics has announced progression in their Phase 2 study on PTG-300 as treatment for patients with polycythemia vera, a rare cancer. Dr.…
One of the goals of treatment for a rare form of non-Hodgkin lymphoma is the delay of disease progression. As reported by Cancer Updates, Research and Education (CARE), a recent…
In the face of COVID-19, considerations and procedures regarding the use of radiation for blood cancer patients may need to be modified. When the risk of severe infections from COVID-19…
According to a story from Financial Buzz, the precision oncology company Notable has recently announced that it has opened enrollment for a new observational clinical trial that will focus on…
.png)
The American Journal of Managed Care (AJMC) published excerpts from a presentation by Dr. Andrew Wei at the 61st American Society of Hematology (ASH) Annual Meeting. The article stated…
.jpg)
According to a recently published article in Targeted Oncology, the results of the Phase III CANDOR trial were presented at the 61st ASH annual conference in Orlando, Florida. The…
.jpg)
According to a recent article in the ASH Clinical News patients are being encouraged to participate in shared decision-making (SDM) with their doctors, nurses and other medical personnel. The…
According to a story from BioSpace, the biopharmaceutical company BeiGene Co., Ltd has recently announced that its drug zanubrutinib (marketed as BRUKINSA) has earned Accelerated Approval from the US Food…
About Graft-Versus-Host-Disease (GvHD) Graft-Versus-Host-Disease (GvHD) occurs when a patient's body rejects cells which have been transplanted. For instance, it may develop following a stem cell transplant or a bone marrow transplant. The…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
